EA201270571A1 - Человеческие il-23-антигенсвязывающие белки - Google Patents
Человеческие il-23-антигенсвязывающие белкиInfo
- Publication number
- EA201270571A1 EA201270571A1 EA201270571A EA201270571A EA201270571A1 EA 201270571 A1 EA201270571 A1 EA 201270571A1 EA 201270571 A EA201270571 A EA 201270571A EA 201270571 A EA201270571 A EA 201270571A EA 201270571 A1 EA201270571 A1 EA 201270571A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antigen
- binding proteins
- human
- encode
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Предусматриваются антигенсвязывающие белки, которые связываются с человеческим IL- 23. Также предусматриваются нуклеиновые кислоты, кодирующие антигенсвязывающий белок, векторы и клетки, кодирующие их, а также применение IL-23- антигенсвязывающих белков для целей диагностики и терапии.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25498209P | 2009-10-26 | 2009-10-26 | |
US38128710P | 2010-09-09 | 2010-09-09 | |
PCT/US2010/054148 WO2011056600A1 (en) | 2009-10-26 | 2010-10-26 | Human il-23 antigen binding proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201270571A1 true EA201270571A1 (ru) | 2012-09-28 |
EA025366B1 EA025366B1 (ru) | 2016-12-30 |
Family
ID=43413789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201270571A EA025366B1 (ru) | 2009-10-26 | 2010-10-26 | Человеческие выделенные il-23-антигенсвязывающие белки, способы их получения и применение |
Country Status (37)
Country | Link |
---|---|
US (9) | US8722033B2 (ru) |
EP (3) | EP2493925B1 (ru) |
JP (5) | JP5930968B2 (ru) |
KR (3) | KR101568461B1 (ru) |
CN (3) | CN104761642A (ru) |
AR (1) | AR078778A1 (ru) |
AU (1) | AU2010315557B2 (ru) |
BR (2) | BR122020002402B8 (ru) |
CA (2) | CA2778112C (ru) |
CL (1) | CL2012001096A1 (ru) |
CO (1) | CO6531481A2 (ru) |
CR (1) | CR20120210A (ru) |
CY (1) | CY1118576T1 (ru) |
EA (1) | EA025366B1 (ru) |
ES (1) | ES2613236T3 (ru) |
HK (2) | HK1177469A1 (ru) |
HR (1) | HRP20170037T1 (ru) |
HU (1) | HUE030871T2 (ru) |
IL (3) | IL219241A (ru) |
JO (1) | JO3244B1 (ru) |
LT (1) | LT2493925T (ru) |
MA (1) | MA33757B1 (ru) |
MX (1) | MX358249B (ru) |
MY (1) | MY156286A (ru) |
NZ (2) | NZ625630A (ru) |
PE (2) | PE20161327A1 (ru) |
PL (1) | PL2493925T3 (ru) |
PT (1) | PT2493925T (ru) |
RS (1) | RS55666B1 (ru) |
SG (2) | SG10202103260TA (ru) |
SI (1) | SI2493925T1 (ru) |
TN (1) | TN2012000167A1 (ru) |
TW (2) | TWI432210B (ru) |
UA (1) | UA113609C2 (ru) |
UY (1) | UY32971A (ru) |
WO (1) | WO2011056600A1 (ru) |
ZA (1) | ZA201203058B (ru) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
CN103338783B (zh) * | 2011-01-25 | 2016-03-09 | 莫奈尔化学感官中心 | 提供或调节甜味的组合物和方法及其筛选方法 |
EP2583979B1 (en) * | 2011-10-19 | 2015-12-16 | Effimune | Methods to prepare antibodies directed against p19 subunit of human IL-23 |
EP4039275A1 (en) * | 2012-05-03 | 2022-08-10 | Boehringer Ingelheim International GmbH | Anti-il-23p19 antibodies |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
CN105209064A (zh) | 2013-03-15 | 2015-12-30 | 美国安进公司 | 使用抗il-23抗体治疗银屑病的方法 |
NZ712294A (en) * | 2013-03-15 | 2020-04-24 | Amgen Inc | Methods for treating crohn’s disease using an anti-il23 antibody |
KR20160138580A (ko) | 2014-04-15 | 2016-12-05 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Wisp1에 결합하는 항원 결합 단백질 |
EP4198059A1 (en) | 2014-05-27 | 2023-06-21 | The University of Queensland | Modulation of cellular stress |
MX2017000527A (es) | 2014-07-14 | 2017-08-10 | Amgen Inc | Formulaciones de anticuerpos cristalinos. |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
US11016099B2 (en) | 2015-09-17 | 2021-05-25 | Amgen Inc. | Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers |
TWI733695B (zh) * | 2015-09-18 | 2021-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
IL258637B1 (en) * | 2015-10-19 | 2024-06-01 | Dyax Corp | An immunoassay for the detection of high molecular weight cleaved kininogen |
CN108472367A (zh) | 2015-12-22 | 2018-08-31 | 美国安进公司 | 作为对il23拮抗剂的临床应答的预测因子的ccl20 |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
WO2019023812A1 (en) * | 2017-08-04 | 2019-02-07 | The Hospital For Sick Children | VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF |
PT3661968T (pt) * | 2017-08-04 | 2022-07-04 | Governing Council Univ Toronto | Plataforma de nanopartículas para administração de anticorpos e vacinas |
TWI744617B (zh) | 2018-03-30 | 2021-11-01 | 美商美國禮來大藥廠 | 治療潰瘍性結腸炎之方法 |
CA3105598A1 (en) | 2018-07-13 | 2020-01-16 | Carl GOMMOLL | Treating ulcerative colitis with brazikumab |
MA56124A (fr) * | 2019-06-04 | 2022-04-13 | Janssen Biotech Inc | Méthode sûre et efficace de traitement de l'arthrite psoriasique au moyen d'un anticorps spécifique anti-il23 |
TW202108629A (zh) * | 2019-06-26 | 2021-03-01 | 圓祥生命科技股份有限公司 | 用於t細胞活化之抗體 |
WO2021126435A1 (en) | 2019-12-20 | 2021-06-24 | Novarock Biotherapeutics, Ltd. | Anti-interleukin-23 p19 antibodies and methods of use thereof |
CN112807428A (zh) * | 2020-06-12 | 2021-05-18 | 江苏荃信生物医药有限公司 | 包含抗人白介素23单克隆抗体的药物组合物 |
WO2022041390A1 (zh) * | 2020-08-28 | 2022-03-03 | 江苏荃信生物医药股份有限公司 | 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法 |
AR123477A1 (es) | 2020-09-10 | 2022-12-07 | Lilly Co Eli | Formulaciones de anticuerpos terapéuticos |
CN114773466B (zh) * | 2020-11-26 | 2023-08-29 | 江苏荃信生物医药股份有限公司 | 一种抗人白介素23及包含其的试剂盒及其检测方法 |
US20220373539A1 (en) * | 2021-05-24 | 2022-11-24 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
AU2022296633A1 (en) * | 2021-06-25 | 2023-12-21 | Sangamo Therapeutics, Inc. | Antigen binders specific for il-23r and uses thereof |
WO2023056417A1 (en) | 2021-09-30 | 2023-04-06 | Eli Lilly And Company | Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis |
CN114994331B (zh) * | 2022-05-17 | 2023-02-24 | 无锡科金生物科技有限公司 | 一种检测蛋白表达水平的试剂盒及其制备方法和应用 |
WO2024077113A1 (en) | 2022-10-06 | 2024-04-11 | Eli Lilly And Company | Methods of treating fatigue in ulcerative colitis |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US6683046B1 (en) | 1989-12-22 | 2004-01-27 | Hoffmann-La Roche Inc. | Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
EP0590076A4 (en) | 1991-06-14 | 1997-02-12 | Dnx Corp | Production of human hemoglobin in transgenic pigs |
DE69224906T2 (de) | 1991-07-08 | 1998-10-29 | Univ Massachusetts | Thermotropes flüssig-kristallines segment-blockcopolymer |
ES2237747T3 (es) | 1991-11-14 | 2005-08-01 | Prionics Ag | Animales transgenicos no humanos que carecen de proteinas prionicas. |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
ES2198414T3 (es) | 1992-10-23 | 2004-02-01 | Immunex Corporation | Procedimientos para preparar proteinas oligomericas solubles. |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
EP1709970A1 (en) | 1995-04-27 | 2006-10-11 | Abgenix, Inc. | Human antibodies against EGFR, derived from immunized xenomice |
ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
US6060284A (en) | 1997-07-25 | 2000-05-09 | Schering Corporation | DNA encoding interleukin-B30 |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
KR100407811B1 (ko) * | 1998-03-17 | 2003-12-01 | 츄가이 세이야꾸 가부시키가이샤 | 인터루킨-6 안타고니스트를 유효성분으로서 함유하는 염증성 장질환의 예방 또는 치료제 |
WO1999054357A1 (fr) | 1998-04-14 | 1999-10-28 | Chugai Research Institute For Molecular Medicine, Inc. | Nouvelle proteine du type cytokine |
EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
CN100529076C (zh) | 1999-09-09 | 2009-08-19 | 先灵公司 | 哺乳动物细胞因子、相关试剂和方法 |
US7090847B1 (en) | 1999-09-09 | 2006-08-15 | Schering Corporation | Mammalian cytokines; related reagents and methods |
EP2108660A1 (en) | 2002-10-30 | 2009-10-14 | Genentech, Inc. | Inhibition of IL-17 production |
AU2003303384A1 (en) | 2002-12-23 | 2004-07-22 | Schering Corporation | Uses of mammalian cytokine; related reagents |
WO2004071517A2 (en) | 2003-02-06 | 2004-08-26 | Schering Corporation | Uses of il-23 related reagents |
AU2004219625B9 (en) | 2003-03-10 | 2010-12-23 | Merck Sharp & Dohme Corp. | Uses of IL-23 agonists and antagonists; related reagents |
WO2004101750A2 (en) | 2003-05-09 | 2004-11-25 | Centocor, Inc. | IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES |
MXPA06012754A (es) | 2004-05-03 | 2007-02-19 | Schering Corp | El uso de la expresion de il-17 para predecir la inflamacion de la piel: metodos de tratamiento. |
US20050287593A1 (en) | 2004-05-03 | 2005-12-29 | Schering Corporation | Use of cytokine expression to predict skin inflammation; methods of treatment |
AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
EP1853707A2 (en) | 2004-12-20 | 2007-11-14 | Schering Corporation | Uses of il-23 antagonists in the treatment of diabetes mellitus |
TWI406943B (zh) | 2004-12-21 | 2013-09-01 | Centocor Inc | 抗-il-12抗體、抗原決定部位、組成物、方法及用途 |
PT2452694T (pt) | 2005-06-30 | 2019-02-21 | Janssen Biotech Inc | Anticorpos anti-il-23, composições, métodos e utilizações |
BRPI0611714A2 (pt) | 2005-06-30 | 2009-01-13 | Abbott Lab | proteÍnas de ligaÇço a il-12/p40 |
DK1937721T3 (da) | 2005-08-25 | 2010-10-18 | Lilly Co Eli | Anti-IL-23 antistoffer |
PL1931710T3 (pl) | 2005-08-31 | 2017-06-30 | Merck Sharp & Dohme Corp. | Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej |
CN1955248B (zh) * | 2005-10-28 | 2011-10-12 | 安集微电子(上海)有限公司 | 钽阻挡层用化学机械抛光浆料 |
CN101389769A (zh) | 2005-12-28 | 2009-03-18 | 森托科尔公司 | 用于评价和治疗银屑病及相关疾病的标记与方法 |
PT1971366E (pt) * | 2005-12-29 | 2014-11-06 | Janssen Biotech Inc | Anticorpos humanos anti-il-23, composições, métodos e usos |
US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
CA2655372A1 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
MX2009007570A (es) * | 2007-01-16 | 2009-07-22 | Abbott Lab | Metodos para tratar la psoriasis. |
TWI426918B (zh) | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
SI2059534T1 (sl) | 2007-02-23 | 2012-08-31 | Schering Corp | Umetno proizvedena anti-il-23p19 antitelesa |
CN101663320A (zh) | 2007-02-23 | 2010-03-03 | 先灵公司 | 工程改造的抗IL-23p19抗体 |
AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
EP2215125A1 (en) | 2007-11-27 | 2010-08-11 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
WO2009082624A2 (en) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
KR20100126515A (ko) | 2008-03-18 | 2010-12-01 | 아보트 러보러터리즈 | 건선의 치료방법 |
WO2010017598A1 (en) | 2008-08-14 | 2010-02-18 | Arana Therapeutics Limited | Anti-il-12/il-23 antibodies |
CN102202655B (zh) | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
CA2757237A1 (en) | 2009-04-01 | 2010-10-14 | Jane Elizabeth Clarkson | Anti-il-23 immunoglobulins |
US20120027799A1 (en) | 2009-04-02 | 2012-02-02 | The Johns Hopkins University | Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer |
US20120264917A1 (en) | 2009-05-27 | 2012-10-18 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
KR20120112384A (ko) | 2009-09-14 | 2012-10-11 | 애보트 게엠베하 운트 콤파니 카게 | 건선을 치료하는 방법 |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
PE20121691A1 (es) | 2010-01-15 | 2012-12-14 | Kirin Amgen Inc | Formulacion de anticuerpos y regimenes terapeuticos |
BR112012019881A2 (pt) | 2010-02-18 | 2017-06-27 | Bristol Myers Squibb Co | proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23 |
EP2596022A4 (en) | 2010-07-20 | 2014-11-05 | Cephalon Australia Pty Ltd | SPECIFIC ANTIBODIES ANTI-HETERODIMER IL-23 |
TW201233395A (en) | 2010-10-06 | 2012-08-16 | Abbott Lab | Methods for treating psoriasis |
KR20130110179A (ko) | 2010-10-08 | 2013-10-08 | 노파르티스 아게 | Il―17 길항제를 사용하는 건선의 치료 방법 |
WO2012061448A1 (en) | 2010-11-04 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Anti-il-23 antibodies |
TW201242976A (en) | 2011-01-07 | 2012-11-01 | Abbott Lab | Anti-IL-12/IL-23 antibodies and uses thereof |
NZ712294A (en) | 2013-03-15 | 2020-04-24 | Amgen Inc | Methods for treating crohn’s disease using an anti-il23 antibody |
US11016099B2 (en) | 2015-09-17 | 2021-05-25 | Amgen Inc. | Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers |
CN108472367A (zh) | 2015-12-22 | 2018-08-31 | 美国安进公司 | 作为对il23拮抗剂的临床应答的预测因子的ccl20 |
CA3105598A1 (en) | 2018-07-13 | 2020-01-16 | Carl GOMMOLL | Treating ulcerative colitis with brazikumab |
EP4017880A4 (en) | 2019-08-21 | 2023-10-11 | Astrazeneca Collaboration Ventures, LLC | USE OF BRAZIKUMAB TO TREAT CROHN'S DISEASE |
-
2010
- 2010-10-18 JO JOP/2010/0356A patent/JO3244B1/ar active
- 2010-10-26 CN CN201510065612.3A patent/CN104761642A/zh active Pending
- 2010-10-26 SG SG10202103260TA patent/SG10202103260TA/en unknown
- 2010-10-26 SG SG10201800682SA patent/SG10201800682SA/en unknown
- 2010-10-26 PE PE2016002001A patent/PE20161327A1/es not_active Application Discontinuation
- 2010-10-26 WO PCT/US2010/054148 patent/WO2011056600A1/en active Application Filing
- 2010-10-26 CA CA2778112A patent/CA2778112C/en active Active
- 2010-10-26 TW TW099136594A patent/TWI432210B/zh not_active IP Right Cessation
- 2010-10-26 PT PT107740953T patent/PT2493925T/pt unknown
- 2010-10-26 NZ NZ625630A patent/NZ625630A/en unknown
- 2010-10-26 CN CN201910176289.5A patent/CN110407936A/zh active Pending
- 2010-10-26 KR KR1020127013696A patent/KR101568461B1/ko active IP Right Grant
- 2010-10-26 LT LTEP10774095.3T patent/LT2493925T/lt unknown
- 2010-10-26 US US13/504,449 patent/US8722033B2/en active Active
- 2010-10-26 TW TW103103013A patent/TW201417830A/zh unknown
- 2010-10-26 PE PE2012000564A patent/PE20121579A1/es active IP Right Grant
- 2010-10-26 AU AU2010315557A patent/AU2010315557B2/en active Active
- 2010-10-26 EA EA201270571A patent/EA025366B1/ru unknown
- 2010-10-26 CA CA3030092A patent/CA3030092C/en active Active
- 2010-10-26 ES ES10774095.3T patent/ES2613236T3/es active Active
- 2010-10-26 NZ NZ599875A patent/NZ599875A/en unknown
- 2010-10-26 MY MYPI2012001807A patent/MY156286A/en unknown
- 2010-10-26 PL PL10774095T patent/PL2493925T3/pl unknown
- 2010-10-26 UA UAA201206355A patent/UA113609C2/uk unknown
- 2010-10-26 BR BR122020002402A patent/BR122020002402B8/pt active IP Right Grant
- 2010-10-26 KR KR1020167022998A patent/KR20160118278A/ko not_active Application Discontinuation
- 2010-10-26 CN CN201080059062.XA patent/CN102741285B/zh active Active
- 2010-10-26 EP EP10774095.3A patent/EP2493925B1/en active Active
- 2010-10-26 EP EP16199576.6A patent/EP3181586A1/en not_active Withdrawn
- 2010-10-26 JP JP2012536968A patent/JP5930968B2/ja active Active
- 2010-10-26 SI SI201031391A patent/SI2493925T1/sl unknown
- 2010-10-26 RS RS20170119A patent/RS55666B1/sr unknown
- 2010-10-26 HU HUE10774095A patent/HUE030871T2/en unknown
- 2010-10-26 MX MX2012004868A patent/MX358249B/es active IP Right Grant
- 2010-10-26 AR ARP100103927A patent/AR078778A1/es active IP Right Grant
- 2010-10-26 UY UY0001032971A patent/UY32971A/es not_active Application Discontinuation
- 2010-10-26 EP EP19202723.3A patent/EP3656790A1/en active Pending
- 2010-10-26 KR KR1020147012130A patent/KR101652609B1/ko active IP Right Grant
- 2010-10-26 BR BR112012009854A patent/BR112012009854B8/pt active IP Right Grant
-
2012
- 2012-04-10 TN TNP2012000167A patent/TN2012000167A1/en unknown
- 2012-04-17 IL IL219241A patent/IL219241A/en active IP Right Grant
- 2012-04-25 ZA ZA2012/03058A patent/ZA201203058B/en unknown
- 2012-04-26 CL CL2012001096A patent/CL2012001096A1/es unknown
- 2012-04-26 CR CR20120210A patent/CR20120210A/es unknown
- 2012-04-26 CO CO12068924A patent/CO6531481A2/es unknown
- 2012-05-18 MA MA34877A patent/MA33757B1/fr unknown
-
2013
- 2013-04-16 HK HK13104578.7A patent/HK1177469A1/xx unknown
-
2014
- 2014-03-28 US US14/228,556 patent/US9487580B2/en active Active
-
2015
- 2015-12-03 JP JP2015236268A patent/JP2016102122A/ja active Pending
-
2016
- 2016-01-06 HK HK16100056.3A patent/HK1212357A1/xx unknown
- 2016-03-28 IL IL244801A patent/IL244801B/en active IP Right Grant
- 2016-09-21 US US15/271,315 patent/US9951129B2/en active Active
-
2017
- 2017-01-10 HR HRP20170037TT patent/HRP20170037T1/hr unknown
- 2017-01-24 CY CY20171100096T patent/CY1118576T1/el unknown
-
2018
- 2018-03-13 JP JP2018045121A patent/JP2018117626A/ja active Pending
- 2018-11-19 US US16/194,896 patent/US20190071498A1/en not_active Abandoned
-
2019
- 2019-06-26 US US16/453,482 patent/US20190322737A1/en not_active Abandoned
- 2019-09-12 JP JP2019166277A patent/JP7023908B2/ja active Active
-
2020
- 2020-02-18 US US16/793,610 patent/US20200181255A1/en not_active Abandoned
- 2020-05-24 IL IL274871A patent/IL274871A/en unknown
- 2020-10-01 US US17/060,905 patent/US20210024626A1/en not_active Abandoned
-
2021
- 2021-04-13 US US17/229,607 patent/US20210230267A1/en not_active Abandoned
- 2021-10-29 JP JP2021177428A patent/JP7278355B2/ja active Active
- 2021-11-12 US US17/525,421 patent/US12012449B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201270571A1 (ru) | Человеческие il-23-антигенсвязывающие белки | |
EA201170204A1 (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
EA201492149A1 (ru) | St2-антигенсвязывающие белки | |
EA201490825A8 (ru) | Tdp-43-специфически связывающие молекулы | |
EA201270713A1 (ru) | Белки на основе фибронектина с каркасными доменами, которые связывают ил-23 | |
EA201300239A1 (ru) | Антитела к fap и способы их применения | |
EA201390095A1 (ru) | ИННОВАЦИОННОЕ ОТКРЫТИЕ ТЕРАПЕВТИЧЕСКИХ КОМПОЗИЦИЙ, ДИАГНОСТИЧЕСКИХ КОМПОЗИЦИЙ И КОМПОЗИЦИЙ АНТИТЕЛ, СВЯЗАННЫХ С БЕЛКОВЫМИ ФРАГМЕНТАМИ ГИСТИДИЛ-тРНК-СИНТЕТАЗ | |
EA201390094A1 (ru) | ИННОВАЦИОННОЕ ОТКРЫТИЕ ТЕРАПЕВТИЧЕСКИХ КОМПОЗИЦИЙ, ДИАГНОСТИЧЕСКИХ КОМПОЗИЦИЙ И КОМПОЗИЦИЙ АНТИТЕЛ, СВЯЗАННЫХ С БЕЛКОВЫМИ ФРАГМЕНТАМИ АСПАРТИЛ-тРНК-СИНТЕТАЗ | |
EA201000357A1 (ru) | Антигенсвязывающие белки, связывающие с-fms человека | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
EA201690504A1 (ru) | Антигенсвязывающие белки к gitr | |
EA201170635A1 (ru) | Композиции, способы получения и применение каркаса на основе домена фибронектина типа iii | |
EA201300558A1 (ru) | Соединения и способы для купирования боли | |
AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
EA201590998A1 (ru) | СВЯЗЫВАЮЩИЕСЯ С EGFR И c-Met МОЛЕКУЛЫ С ДОМЕНАМИ ФИБРОНЕКТИНА ТИПА III | |
EA201690310A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
EA201590910A1 (ru) | Белки на основе структурного домена фибронектина, связывающие pcsk9 | |
EA201590138A1 (ru) | Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение | |
EA201391632A1 (ru) | Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды | |
EA201170205A1 (ru) | Антитела, нейтрализующие цитомегаловирус человека, и их применение | |
EA201390689A1 (ru) | Консенсусные антигены простаты, молекула нуклеиновой кислоты, кодирующая их, и вакцина, и использование, включающее их | |
EA201390993A1 (ru) | Антитела к cd38 | |
ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
EA201391019A1 (ru) | Соединения и способы для модуляции киназ, а также показания к их применению | |
EA201590247A1 (ru) | Антитела к siglec-15 |